ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1981 • 2018 ACR/ARHP Annual Meeting

    A Molecular Bayesian Network for Rheumatoid Arthritis Reveals Multiple Candidate Key Regulators for Disease Severity

    Wenhui Wang1, Amit Lahiri2, Teresina Laragione2, Jun Zhu1 and Percio S. Gulko2,3, 1Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune joint disease. RA is pathologically heterogeneous with multiple contributing factors. While there has been a…
  • Abstract Number: 70 • 2018 ACR/ARHP Annual Meeting

    Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients

    Geoffrey M. Thiele1, Michael J. Duryee2, Jacob D. McGowan1, Logan M. Duryee1, Lynell W. Klassen3, James R. O'Dell3, Bryant R. England4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 4Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:   Malondialdehyde-acetaldehyde adducts (MAA) are products of oxidative stress that modify self-proteins and stimulate potent cellular and humoral immune responses. We have previously demonstrated…
  • Abstract Number: 1982 • 2018 ACR/ARHP Annual Meeting

    An Integrative Rheumatoid Arthritis Network for Elucidating Molecular Mechanisms Underlying RA Severity

    Wenhui Wang1, Teresina Laragione2, Amit Lahiri2, Jun Zhu1 and Percio S. Gulko3, 1Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, 2Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a pathologically heterogeneous disease with multiple contributing factors. Many models have been developed to study RA severity and progression, and…
  • Abstract Number: 520 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program

    Lucia C. Domínguez-Casas1, Paz Rodríguez-Cundín2, Vanesa Calvo-Río3, Nuria Vegas-Revenga3, Virginia Portilla4, F. Antolin2, M. Rebollo-Rodrigo2, Alfonso Corrales1, Diana Prieto Peña3, Monica Calderón Goercke3, Miguel Angel González-Gay1 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain, 3Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Rheumatoid arthritis(RA) patients are at increased risk of infections particularly respiratory infections. These may be augmented due to RA itself and to immunosuppressive durgs,…
  • Abstract Number: 2047 • 2018 ACR/ARHP Annual Meeting

    Synovial Fluid Cytokines /Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients Which Correlate with the Magnitude of the Inflammatory Response As Measured By Synovial Fluid WBC Levels

    Richard Meehan1, Eric Hoffman2, Mary Wolf3, Elizabeth Regan4, Prashant Parmar5, Karin Pacheco6, Jim Crooks7 and Vijaya Knight8, 1MEDICINE, National Jewish Health, Denver, CO, 2Medicine/Rheumatology, National Jewish Health, Denver, CO, 3Pathology Department, National Jewish Health, Denver, CO, 4Medicine, National Jewish Health, Denver, CO, 5Internal Medicine, St Joseph Hospital, Denver, CO, 6MEDICINE/ Occupational Medince, National Jewish Health, Denver, CO, 7Biostatistics, National Jewish Health, Denver, CO, 8Pathology, ADX laboratory, National Jewish Health, Denver, CO

    Background/Purpose: Synovial fluid (SF) provides nutritional support for cartilage and contains numerous catabolic and anabolic cytokines, chemokines and proteins. The precise role of these proteins…
  • Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting

    Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-

    Kosuke Ebina1, Makoto Hirao2, Motomu Hashimoto3, Wataru Yamamoto4, Akira Onishi5, Toru Hirano6, Ryota Hara7, Masaki Katayama8, Shuzo Yoshida9, Koji Nagai9, Yonsu Son10, Hideki Amuro10, Kengo Akashi11, Koichi Murata3, Kosaku Murakami12, Keiichi Yamamoto13 and Hideki Yoshikawa14, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 5Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, 7The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, 8Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, 9Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, 10First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 11Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 12Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Department of Medical Statistics, Osaka City University, Osaka, Japan, 14Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
  • Abstract Number: 2353 • 2018 ACR/ARHP Annual Meeting

    Attitudes and Beliefs Regarding Methotrexate in Patients with Rheumatoid Arthritis: Results from Australian Rheumatology Association Database

    Nieves Leonardo1,2, Susan Lester3,4, Michelle Graham5, Samuel Whittle1,6, Debra Rowett7,8, Rachelle Buchbinder9,10 and Catherine Hill6,11,12, 1Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, 2Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, 3Rheumatology Unit, The Queen Elizabeth Hospital, Adelaide, Australia, 4Discipline of Medicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia, 5Arthritis Queensland, Queensland, Australia, 6The Queen Elizabeth Hospital, Adelaide, Australia, 7School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, 8Drug and Therapeutics Information Service, Southern Adelaide Local Health Network, Adelaide, Australia, 9Cabrini Institute, Victoria, Australia, 10Monash University, Melbourne, Australia, 11Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 12Medicine, The University of Adelaide, Adelaide, Australia

    Background/Purpose: To determine beliefs about methotrexate (MTX) in patients with Rheumatoid Arthritis (RA) in relation to views obtained from a range of information sources.Methods: RA…
  • Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting

    Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up

    Sebastian C Rodriguez-Garcia1, Raul Castellanos-Moreira Sr.1, José Inciarte-Mundo2, M. Victoria Hernández3, Virginia Ruiz-Esquide2, Andrea Cuervo1, Julio Ramírez2, Juan Cañete1, Jose Gomez Puerta1 and Raimon Sanmartí1, 1Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, 3Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain

    Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
  • Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting

    Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort

    Zulema Rosales Rosado1,2, Judit Font Urgelles1, Pia Mercedes Lois1, Cristina Vadillo Font1, Dalifer Freites Núñez2, Isabel Hernández-Rodríguez1, Juan A Jover Jover1 and Lydia A Alcazar2, 1Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain

    Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
  • Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting

    Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation

    Gyanendra Pokharel1, Rob Deardon1, Sindhu Johnson2, George A. Tomlinson3 and Glen Hazlewood4, 1Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, 2Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 3Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
  • Abstract Number: 2522 • 2018 ACR/ARHP Annual Meeting

    Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

    Stanley Cohen1, Niklas Czeloth2, Eric Lee3, Piotr A. Klimiuk4, Nuala Peter5 and Girish Jayadeva2, 1Metroplex Clinical Research Center, Dallas, TX, 2Boehringer Ingelheim, Ingelheim a.R., Germany, Ingelheim, Germany, 3Inland Rheumatology, Upland, CA, 4Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, 5Boehringer Ingelheim, Biberach a.d.R., Germany, Ingelheim a.R., Germany

    Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…
  • Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting

    Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database

    Elliot Hepworth1, Mohammad Movahedi2, Emmanouil Rampakakis3, Reza Mirza1, Arthur Lau4, Angela Cesta5, Janet E. Pope6 and Claire Bombardier7, 1Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3JSS Medical Research, Montreal, QC, Canada, 450 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
  • Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting

    Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)

    Paula Fortea-Gordo1, Laura Nuño2, Alejandro Villalba2, Diana Peiteado3, Irene Monjo4, Paloma Sanchez-Mateos5, Amaya Puig-Kröger6, Alejandro Balsa1 and Maria Eugenia Miranda-Carus1, 1Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, 2Rheumatology, La Paz University Hospital, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain, 4Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 5Immunology, Hospital Gregorio Marañon, Madrid, Spain, 6Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain

    Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
  • Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

    Song-Chou Hsieh1, Yi-Hsing Chen2, Wei-Sheng Chen3, Wen-Chan Tsai4, Jui-Chieh Hu5, Hsiang-Cheng Chen6, Jack Mardekian7 and Chacun Lai8, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taichung Veterans General Hospital, Taichung City, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 6National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, 7Pfizer Global Biometrics & Data Management, NY, NY, 8Pfizer PFE Limited, New Taipei, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
  • Abstract Number: 2900 • 2018 ACR/ARHP Annual Meeting

    Impaired TCR Signaling Paves the Way for Cytokine Hyper-Responsiveness in Arthritogenic T Cells

    Judith Ashouri1, Lih-Yun Hsu1, Dmitry Rychkov2, Marina Sirota2, Lisa Lattanza3, Eric Hansen3, Julie Zikherman1 and Arthur Weiss1, 1Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, 3Orthopedic Surgery, University of California, San Francisco, San Francisco, CA

    Background/Purpose: The inability to identify relevant arthritogenic CD4 T cells in patients and in murine disease models has limited our understanding of disease initiating events…
  • « Previous Page
  • 1
  • …
  • 169
  • 170
  • 171
  • 172
  • 173
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology